Bromocriptine | 25614-03-3

Bromocriptine Properties

Melting point	215-218° (dec)
alpha	D20 -195° (c = 1 in methylene chloride)
Boiling point	891.3±65.0 °C(Predicted)
Density	1.2734 (rough estimate)
refractive index	1.6400 (estimate)
pka	pKa 4.90±0.05(80% MCS t = RT) (Uncertain)
Water Solubility	2.07mg/L(temperature not stated)
CAS DataBase Reference	25614-03-3(CAS DataBase Reference)
FDA UNII	3A64E3G5ZO
ATC code	G02CB01,N04BC01
NCI Drug Dictionary	Parlodel

Pharmacokinetic data

Protein binding	90-96%
Excreted unchanged in urine	2.5-5.5%
Volume of distribution	1-3(L/kg)
Biological half-life	8-20 / -

SAFETY

Risk and Safety Statements

Symbol(GHS)	GHS07,GHS08
Signal word	Warning
Hazard statements	H361-H362-H302
Precautionary statements	P201-P202-P281-P308+P313-P405-P501-P264-P270-P301+P312-P330-P501-P201-P260-P263-P264-P270-P308+P313
Toxicity	An ergot alkaloid derivative that exhibits potent dopamine agonist properties, particularly at D2 dopamine receptors. Bromocriptine, like dopamine, inhibits prolactin release from the pituitary and so is used in endocrine disorders, such as hyperprolactinemia. It is also used in the treatment of Parkinson’s disease. A large “first-pass” effect is seen with bromocriptine, and peak concentrations occur about 1.5-3 h after ingestion, with a half-life of about 3 h. Nausea, vomiting, and orthostatic hypotension are among the acute adverse effects. Long-term use has been associated with dyskinesias, constipation, psychoses, digital spasm, and erythromelalgia. The LD50 in rabbits exceeds 1 g/kg, p.o., and 12 mg/kg, i.v.

Bromocriptine Chemical Properties,Uses,Production

Chemical Properties

Crystals.

Originator

Parlodel,Sandoz,UK,1975

Uses

Enzyme inhibitor (prolactin).

Uses

Bromocriptine, a dopaminomimetic that is a dopamine D2 receptor agonist, possesses expressed antiparkinsonian activity. It is used for treating all phases of idiopathic and postencephalic Parkinsonism.

Definition

An semisynthetic ergotamine alkaloid derivative and powerful dopamine D2 agonist. It inhibits prolactin secretion and release from the pituitary and retards tumor growth.

Manufacturing Process

A solution of 3.4 grams of N-bromosuccinimide in 60 cc of absolute dioxane is added drop wise in the dark, during the course of 5 minutes, to a stirred solution, heated to 60°C, of 9.2 grams of ergocryptine in 180 cc of absolute dioxane. The reaction mixture is stirred at this temperature for 70 minutes and is concentrated to a syrup-like consistency in a rotary evaporator at a bath temperature of 50°C. The reaction mixture is subsequently diluted with 300 cc of methylene chloride, is covered with a layer of about 200 cc of a 2 N sodium carbonate solution in a separating funnel and is shaken thoroughly. The aqueous phase is extracted thrice with 100 cc amounts of methylene chloride. The combined organic phases are washed once with 50 cc of water, are dried over sodium sulfate and the solvent is removed under a vacuum.
The resulting brown foam is chromatographed on a 50-fold quantity of aluminum oxide of activity II-III with 0.2% ethanol in methylene chloride as eluant, whereby the compound indicated in the heading is eluted immediately after a secondary fraction which migrates somewhat more rapidly than the fractions containing the heading compound. The last fractions to leave the aluminum oxide contain varying amounts of starting material together with the heading compound, and may be subjected directly, as mixed fractions, to an afterbromination in accordance with the method described above. The fractions containing the pure heading compound are combined and crystallized from methyl ethyl ketonehopropy1 ether. Melting point 215°-218°C (decomp.), [α]D 20-195° (c = 1 in methylene chloride).

brand name

Parlodel (Novartis);Bromed;Lactismine;Parilac;Umprel.

Therapeutic Function

Prolactin inhibitor

World Health Organization (WHO)

Bromocriptine, a semisynthetic ergot alkaloid derivative and prolactin inhibitor was introduced into medicine in 1976. It is used in the prevention of lactation, but because of the risk of rebound effect and since only 10% of women benefit therapeutically from such intervention, the United States Food and Drug Administration has requested manufacturers to no longer indicate preparations containing bromocriptine for this purpose. The World Health Organization is not aware of similar action having been taken elsewhere.

Hazard

Poison; teratogen; developmental abnor- malities of the respiratory system,musculoskeletal system, rogenital system, craniofacial area, and body wall; teratogen; mutagen; questionable car- cinogen; tumorigen; causes nausea, vomiting, orthostatic hypotension; constipation, dyskinesias, psychoses, digital spasm, erythromelalgia.

Mechanism of action

Bromocriptine is absorbed after oral administration, but approximately 90% of a dose undergoes extensive first-pass hepatic metabolism, with the remainder hydrolyzed in the liver to inactive metabolites that are eliminated mostly in the bile. The half-life is relatively short (~3 hours).

Clinical Use

Bromocriptine is an ergot peptide derivative that is a partial agonist at D1-type and a full agonist at D2-type postsynaptic dopamine receptors, usually given in combination with levodopa therapy. It was the first direct dopamine receptor agonist used in treatment of Parkinson's disease after its development as an inhibitor of prolactin release (via activation of anterior pituitary D2 receptors). At low doses (typically 1–5 mg/day), bromocriptine is an effective prolactin inhibitor, and at higher doses (typically 10–20 mg/day), the antiparkinsonism and mood-elevating effects of bromocriptine become apparent.

Side effects

Bromocriptine has a number of undesirable side effects, even causing mental disturbances in long-term use.

Synthesis

Bromocriptine, 2-bromoergocriptine (10.1.13), is a semisynthetic derivative of a natural ergot alkaloid, ergocriptin (a derivative of lysergic acid), which is synthesized by bromination of ergocriptin using N-bromosuccinimide [18,19].

Synthesis_25614-03-3

Drug interactions

Potentially hazardous interactions with other drugs
Increased risk of toxicity with bromocriptine and isometheptene.

Metabolism

Bromocriptine is extensively metabolised. It undergoes extensive first-pass biotransformation in the liver, reflected by complex metabolite profiles and by almost complete absence of parent drug in urine and faeces. In plasma the elimination half life is 3-4 hours for the parent drug and 50 hours for the inactive metabolites.The parent drug and its metabolites are also completely excreted via the liver with only 6% being eliminated via the kidney.

Bromocriptine Preparation Products And Raw materials

Raw materials

Imine BROMOSUCCINIC ACID ALPHA-ERGOCRYPTINE N-Bromosuccinimide

Preparation Products

Bromocriptine Suppliers

Global( 65)Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
Hebei Yanxi Chemical Co., Ltd.	+8617531190177	peter@yan-xi.com	China	5993	58
hebei hongtan Biotechnology Co., Ltd	+86-86-1913198-3935 +8617331935328	sales03@chemcn.cn	China	951	58
career henan chemical co	+86-0371-86658258	sales@coreychem.com	China	29914	58
Shanghai Longyu Biotechnology Co., Ltd.	+8615821988213	info@longyupharma.com	China	2531	58
Chongqing Chemdad Co., Ltd	+86-023-61398051 +8613650506873	sales@chemdad.com	China	39916	58
Xi'an MC Biotech, Co., Ltd.	029-89275612 +8618991951683	mcbio_sales@163.com	China	2255	58
Dideu Industries Group Limited	+86-29-89586680 +86-15129568250	1026@dideu.com	China	29576	58
Dayang Chem (Hangzhou) Co.,Ltd.	571-88938639 +8617705817739	info@dycnchem.com	CHINA	52867	58
Hangzhou Huarong Pharm Co., Ltd.	571-86758373 +8613588754946	sales@huarongpharm.com	CHINA	3149	58
LEAP CHEM CO., LTD.	+86-852-30606658	market18@leapchem.com	China	24738	58

Supplier	Advantage
Hebei Yanxi Chemical Co., Ltd.	58
hebei hongtan Biotechnology Co., Ltd	58
career henan chemical co	58
Shanghai Longyu Biotechnology Co., Ltd.	58
Chongqing Chemdad Co., Ltd	58
Xi'an MC Biotech, Co., Ltd.	58
Dideu Industries Group Limited	58
Dayang Chem (Hangzhou) Co.,Ltd.	58
Hangzhou Huarong Pharm Co., Ltd.	58
LEAP CHEM CO., LTD.	58

View Lastest Price from Bromocriptine manufacturers

Update time	Product	Price	Min. Order	Purity	Supply Ability	Manufacturer
2024-04-12	Bromocriptine 25614-03-3	US $30.00 / kg	1kg	98%	2000kg	hebei hongtan Biotechnology Co., Ltd
2023-09-27	bromocriptine 25614-03-3	US $40.00-40.00 / kg	1kg	0.99	10 tons	Hebei Yanxi Chemical Co., Ltd.
2021-07-28	Bromocriptine USP/EP/BP 25614-03-3	US $1.10 / g	1g	99.9%	100 Tons min	Dideu Industries Group Limited

Bromocriptine
25614-03-3
US $30.00 / kg
98%
hebei hongtan Biotechnology Co., Ltd

bromocriptine
25614-03-3
US $40.00-40.00 / kg
0.99
Hebei Yanxi Chemical Co., Ltd.

Bromocriptine USP/EP/BP
25614-03-3
US $1.10 / g
99.9%
Dideu Industries Group Limited

25614-03-3(Bromocriptine)Related Search:

Allyl bromide 3-Bromoanisole 3-Bromopropyne CHLOROPHOSPHONAZO III ALPHA-ERGOCRYPTINE

Cyclopropyl bromide Bromocriptine mesylate EP,(+)-BROMOCRIPTINE MESYLATE,BROMOCRIPTINE MESYLATE,(+)-BROMOCRIPTINE METHANESULFONATE,BROMOCRIPTINE METHANESULPHONATE 2-Bromopropane BroMocriptine IMpurity E Ergoline-8-carboxylic acid, 2-bromo-9,10-didehydro-6-methyl-, (8β)-

BroMocriptine IMpurity F BroMocriptine-13C-d3 BroMocriptine IMpurity G Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (2'β,5'α,8α)- (9CI) 5'alpha(S)-sec-butyl-12'-hydroxy-2'-isopropylergotaman-3',6',18-trione

(8S)-2-BroMo α-Ergocryptine Bromocriptine Impurity A (Mixture of Diastereomers) Bromocriptine Impurity 2

1of4

(5’-alpha)-ropyl) ,6’,18-trione 2-bromo-12’-hydroxy-2’-(1-methylethyl)-5’-alpha-(2-methylpropyl)ergotamin-3’ 2-bromo-alpha-ergocryptine 2-bromo-alpha-ergokryptin 2-bromo-alpha-ergokryptine 2-bromoergocryptine alpha-bromoergocriptine bromergocryptine bromocriptin bromoergocriptine ergotaman-3’,6’,18-trione,2-bromo-12’-hydroxy-2’-(1-methylethyl)-5’-(2-methylp (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione Kripton BROMOCRIPTINE Bromoergocryptine mesylate 2-Bromo-α-ergokryptine bromocripitine Ergocryptine, 2-bromo- (8CI) 2-Bromo-α-ergokryptin ErgotaMan-3',6',18-trione,2-broMo-12'-hydroxy-2'-(1-Methylethyl)-5'-(2-Methylpropyl)-, (5'a)- (5'a)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-ergotaman-3',6',18-trione Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'α)- SAN 15-754 Sandoz 15-754 Bromocriptine\n\nDiscontinued, B682600 BromocriptineQ: What is Bromocriptine Q: What is the CAS Number of Bromocriptine Q: What is the storage condition of Bromocriptine Q: What are the applications of Bromocriptine Bromocriptine USP/EP/BP 2-bromo-ergocryptin bromocryptine bromoergocryptine Parlodel BROMOCRITINE 25614-03-3 25614-03-2 C32H40BrN5O5 Organics